What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Reference-name product · composition documented per batch
Overview
Klow is a reference-name product appearing in upstream price tables under a commercial brand designation rather than a publicly defined chemical name. Three different vial sizes (5, 10, 80 mg) are offered, suggesting Klow is positioned for both pilot-scale and bulk-distributor workflows. As with ADMAX, PROSTAMAX, and the other reference-name SKUs in the catalog, the actual API identity, peptide sequence, and CAS designation is verified against the batch-specific COA before any order placement. PeptideXpo lists Klow to support distributor partners whose upstream price tables reference these commercial brands. The 80 mg fill size in particular suggests bulk-distributor workflows. Direct end-buyers should request the verified composition disclosure from the regulatory team before placing an order, and the batch COA's component-level analysis is the operative document for any downstream regulatory or quality work.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: regional distributors and re-sellers.
Specifications
Documentation available on request
Regulatory note
Reference-name product without publicly disclosed API identity; composition is documented on the batch-specific COA before any downstream regulatory or research use.
Frequently asked questions
The 80 mg fill targets bulk-distributor workflows that benefit from larger per-vial quantities for downstream fractionation or for direct use in higher-dose preparation contexts. The 5 mg and 10 mg fills cover pilot-scale and standard dispensing workflows respectively. As with all reference-name SKUs, the API identity and composition is verified against the batch-specific COA at receipt; the fill-size choice is independent of identity confirmation. For buyers needing the largest possible per-vial quantity, the 80 mg Klow fill is among the larger formats in the reference-name SKU family.
Fractionating an 80 mg lyophilized bulk vial into smaller dispensing units requires controlled sterile-fill capability: reconstitution of the bulk lyophilizate in sterile diluent, sterile-filtration of the reconstituted solution, aliquot fill into smaller vials under ISO 7/8 cleanroom conditions, and terminal re-lyophilization in the smaller vials. Buyers without in-house sterile-fill infrastructure should use PeptideXpo's pre-fractionation OEM service rather than attempting in-house fractionation, the service splits the 80 mg batch into buyer-specified smaller fills (typically 5 mg, 10 mg, or 20 mg per smaller vial) under validated cleanroom conditions. The OEM-service approach is operationally simpler and the per-vial-output documentation chain is cleaner than the in-house path.
First-time Klow orders follow the standard 14-21 day production schedule from confirmed PO. Repeat orders against an established synthesis route compress to 10-14 days. The 80 mg fill in particular benefits from recurring-order economics, bulk production at this fill size is most cost-efficient when scheduled against a quarterly or semi-annual procurement cycle rather than ad-hoc single orders. Distributor partners with regular Klow procurement should discuss the schedule at quote stage; PeptideXpo can hold released-batch inventory against forecast orders for the largest-volume distributors, further compressing effective lead time.
